Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan-Reference-Cited by-同舟云学术

Gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan

Published:2021-07-02 Issue:11 Volume:17 Page:3975-3981
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Ishimaru Tomohiro¹^ORCID,Okawara Makoto¹,Ando Hajime²,Hino Ayako³,Nagata Tomohisa⁴,Tateishi Seiichiro⁵,Tsuji Mayumi⁶,Matsuda Shinya⁷,Fujino Yoshihisa¹,

Affiliation:

1. Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan

2. Department of Work Systems and Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan

3. Department of Mental Health, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan

4. Department of Occupational Health Practice and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan

5. Department of Occupational Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

6. Department of Environmental Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

7. Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Funder

University of Occupational and Environmental Health, Japan

General Incorporated Foundation

Health, Labour and Welfare Sciences Research

Comprehensive Research for Women’s Healthcare

Chugai Pharmaceutical Co., Ltd

Collabo-Health Study Group

Hitachi Systems, Ltd

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1947098

Reference37 articles.

1. Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows

2. Developing Covid-19 Vaccines at Pandemic Speed

3. Prime Minister of Japan and His Cabinet. Novel coronavirus vaccines. Tokyo. 2021 Feb 17 [accessed 2021 Apr 1]. https://japan.kantei.go.jp/ongoingtopics/vaccine.html#vaccine05.

4. Clusters of Coronavirus Disease in Communities, Japan, January–April 2020

5. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gendered (SDG5) and other perspectives on COVID-19 vaccination status: a focus on South Africa's Limpopo province;Frontiers in Global Women's Health;2024-07-30

2. Sağlık Çalışanlarının Aşılanma Durumları ve COVID-19 3;Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi;2024-06-29

3. COVID-19 vaccine acceptance in the general population and under-resourced communities from high-income countries: realist review;BMJ Open;2024-04

4. The THE EFFECT OF KNOWLEDGE AND PERCEPTION ON MOTIVATION TO RECEIVE COVID-19 VACCINE AMONG GENERATIONS;Journal of Child, Family, and Consumer Studies;2024-01-31

5. The refusal of COVID-19 vaccination and its associated factors: a meta-analysis;F1000Research;2024-01-29